EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Orismilast, a Potent and Selective PDE4B /D Inhibitor, Reduces Protein Levels of Key Disease Driving Cytokines in the Skin of Patients With Plaque Psoriasis

Richard B Warren, Anne Weiss iD, Jakob Felding, Morten O A Sommer iD, Sandra Garcet iD, James G Krueger iD

Experimental Dermatology · 2025

DOI: 10.1111/exd.70153 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Experimental Dermatology, 2025. Verfasst von Richard B Warren und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester, Manchester, UK. Hauptthemen laut MEDLINE: Cytokines, Phosphodiesterase 4 Inhibitors, Psoriasis, Skin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UNION therapeutics A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Minimally invasive sampling of the skin using tape strips for conducting biomarker research is a growing research area in medical dermatology. The goal of this study was to utilise tape strip sampling to investigate changes in protein skin levels of psoriasis patients after oral treatment with orismilast (a PDE4B/D inhibitor). The proteins were measured in extracts of tape‐strip samples taken from the skin of patients with moderate–severe psoriasis participating in a 16‐week Ph2b study (IASOS). The proteins were measured using the Olink technology or an ELISA assay. Our results show that protein levels of multiple proteins (32/71) were upregulated at baseline in the lesional skin compared to non‐lesional skin, including three key biomarkers of the psoriasis disease pathology (IL‐17A, CCL20 and TNFα). The protein levels of these three biomarkers were significantly reduced at Week 16, reaching a percent reduction of 52% and 51% for IL‐17A, 66% and 60% for TNFα, and 41% and 54% for CCL20 for the two doses analysed (20 and 30 mg bid, respectively). In addition, we observed that the clinical response of a 75% reduction in PASI (PASI75) was associated with a 98% reduction in IL‐17A protein levels in lesional skin, irrespective of the orismilast dose. In summary, a significant reduction of key proteins related to the T H 17 axis and T H 1 axis was observed in the skin of psoriasis patients after treatment with oral orismilast, supporting the observed clinical effect. Finally, this constitutes the first report where protein levels from the skin of psoriasis patients are quantified using tape strips as a minimally invasive skin sampling technology in combination with the Olink technology. Trial Registration: ClinicalTrials.gov identifier: NCT05190419

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CytokinesPhosphodiesterase 4 InhibitorsPsoriasisSkinAdultFemaleHumansMaleMiddle AgedBiomarkersChemokine CCL20Interleukin-17Tumor Necrosis Factor-alpha

Stichwörter der Autor:innen

IASOSPDE4PDE4 B/D selectivebiomarkerorismilastpsoriasis

Substanzen

BiomarkersCCL20 protein, humanChemokine CCL20CytokinesIL17A protein, humanInterleukin-17Phosphodiesterase 4 InhibitorsTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester, Manchester, UK.
  • UNION Therapeutics A/S, Hellerup, Denmark.
  • Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark (DTU), Lyngby, Denmark.
  • Laboratory of Investigative Dermatology, The Rockefeller University, New York, New York, USA.

ORCID-Profile: Anne Weiss, Morten O A Sommer, Sandra Garcet, James G Krueger

Förderung

  • UNION therapeutics A/S

Zitieren

APA

Warren, R. B., Weiss, A., Felding, J., Sommer, M. O. A., Garcet, S., & Krueger, J. G. (2025). Orismilast, a Potent and Selective PDE4B /D Inhibitor, Reduces Protein Levels of Key Disease Driving Cytokines in the Skin of Patients With Plaque Psoriasis. Experimental Dermatology. https://doi.org/10.1111/exd.70153

Vancouver

Warren RB, Weiss A, Felding J, Sommer MOA, Garcet S, Krueger JG. Orismilast, a Potent and Selective PDE4B /D Inhibitor, Reduces Protein Levels of Key Disease Driving Cytokines in the Skin of Patients With Plaque Psoriasis. Experimental Dermatology. 2025. doi:10.1111/exd.70153

BibTeX
@article{Warren2025,
  author = {Warren, Richard B and Weiss, Anne and Felding, Jakob and Sommer, Morten O A and Garcet, Sandra and Krueger, James G},
  title = {Orismilast, a Potent and Selective PDE4B /D Inhibitor, Reduces Protein Levels of Key Disease Driving Cytokines in the Skin of Patients With Plaque Psoriasis},
  journal = {Experimental Dermatology},
  year = {2025},
  doi = {10.1111/exd.70153}
}
Kostenlos starten →